Exercise Prehabilitation for Locoregional Esophageal Cancer

Launched by H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE · May 21, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at how exercise "prehabilitation" can help patients with esophageal cancer who are preparing for surgery. Prehabilitation means getting patients physically ready before their treatment starts, which might include exercise to improve their strength and overall health. The study aims to see if this approach is practical and acceptable for patients facing surgery after receiving chemotherapy and radiation treatment.

To be eligible for this trial, participants need to have a confirmed diagnosis of locoregional esophageal cancer and be in reasonably good health (a performance status of 0-2, meaning they can do normal activities with little to no difficulty). They should also be able to read and speak English. However, people who already do regular strength training or have certain health issues that could make exercise unsafe will not be able to join. If you participate, you can expect to engage in a structured exercise program designed to prepare you for your upcoming surgery. This trial is currently recruiting participants, and it could be an important step in improving care for patients with esophageal cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Biopsy-proven locoregional esophageal cancer (LEC)
• • Eastern Cooperative Oncology Group (ECOG) performance status 0-2
• • Treatment plan including neoadjuvant chemoradiation therapy and surgical resection
• • Ability to read and speak English
• Exclusion Criteria:
• • Regular engagement in resistance training (2x/week targeting all major muscle groups)
• • Screen failure for exercise safety based on PAR-Q
• • Underlying unstable cardiac or pulmonary disease or symptomatic cardiac disease
• • Recent fracture or acute musculoskeletal injury that precludes ability to participate in resistance training safely
• • Numeric pain rating scale of 7 or more out of 10
• • Myopathic or rheumatologic disease that impacts physical function

Trial Officials